Cite

HARVARD Citation

    Thompson, P. et al. (2018). Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert opinion on investigational drugs. pp. 31-42. [Online]. 
  
Back to record